This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crump, C. Articles by Karlan, B. Y. Search for Related Content PubMed PubMed Citation Articles by Crump, C. Articles by Karlan, B. Y.

Ovarian Cancer Tumor Marker Behavior in Asymptomatic Healthy Women: Implications for Screening

Department of Biostatistics, University of Washington, Seattle, Washington 98195 [C. C., M. W. M., G. A.]; Cancer Prevention Research Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 [M. W. M., N. U., G. A.]; and Department of Obstetrics and Gynecology at Cedars-Sinai Medical Center and the University of California, Los Angeles, California 90048 [B. Y. K.]

Ovarian cancer screening protocols generally have been limited by inadequate recognition of the normal behavior of tumor markers in women at risk of ovarian cancer. We have characterized the behavior of five serum tumor markers in a large cohort of healthy women and examined the implications for screening. Serial measurements of CA125, HER-2/neu, urinary gonadotropin peptide, lipid-associated sialic acid, and Dianon marker 70/K were obtained during 6 years of follow-up of 1257 healthy women at high risk of ovarian cancer. We analyzed individual-specific tumor marker behavior and explored methods that can exploit this information to develop individual-specific screening rules. These five tumor markers behaved approximately independently. Substantial heterogeneity was observed among women in the behavior of each tumor marker, particularly CA125. Intraclass correlation (ICC), or the proportion of total variability that occurs between individuals, was approximately 0.6 for log-transformed CA125 and urinary gonadotropin peptide, and less than 0.4 for the other markers. This degree of tumor marker heterogeneity among healthy women, and the relative independence of these markers, has important implications for screening and diagnostic tests. Independence of markers results in the clinically useful fact that the combined false positive rate from screening with multiple markers may be estimated by the sum of individual false positive rates. Heterogeneity of tumor marker patterns in healthy women implies that a fixed screening cutoff level is suboptimal to a degree that depends strongly on ICC. Using information on longitudinal measurements and ICC, individual-specific screening rules may be developed with the potential to improve early detection of ovarian cancer.

This article has been cited by other articles:

				M. W. McIntosh, Y. Liu, C. Drescher, N. Urban, and E. P. Diamandis Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma Clin. Cancer Res., August 1, 2007; 13(15): 4422 - 4428. [Abstract] [Full Text] [PDF]

				B. Y. Karlan and M. McIntosh The Quest for Ovarian Cancer's Holy Grail: Can CA-125 Still Be the Chalice of Early Detection? J. Clin. Oncol., April 10, 2007; 25(11): 1303 - 1304. [Full Text] [PDF]

				S. G Baker, B. S Kramer, M. McIntosh, B. H Patterson, Y. Shyr, and S. Skates Evaluating markers for the early detection of cancer: overview of study designs and methods Clinical Trials, February 1, 2006; 3(1): 43 - 56. [Abstract] [PDF]

				Z. Amoura, P. Duhaut, D. L. T. Huong, B. Wechsler, N. Costedoat-Chalumeau, C. Frances, P. Cacoub, T. Papo, S. Cormont, Y. Touitou, et al. Tumor Antigen Markers for the Detection of Solid Cancers in Inflammatory Myopathies Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1279 - 1282. [Abstract] [Full Text] [PDF]

				S. J. Skates, N. Horick, Y. Yu, F.-J. Xu, A. Berchuck, L. J. Havrilesky, H. W.A. de Bruijn, A. G.J. van der Zee, R. P. Woolas, I. J. Jacobs, et al. Preoperative Sensitivity and Specificity for Early-Stage Ovarian Cancer When Combining Cancer Antigen CA-125II, CA 15-3, CA 72-4, and Macrophage Colony-Stimulating Factor Using Mixtures of Multivariate Normal Distributions J. Clin. Oncol., October 15, 2004; 22(20): 4059 - 4066. [Abstract] [Full Text] [PDF]

				I. J. Jacobs and U. Menon Progress and Challenges in Screening for Early Detection of Ovarian Cancer Mol. Cell. Proteomics, April 1, 2004; 3(4): 355 - 366. [Abstract] [Full Text] [PDF]

				M. W. McIntosh, N. Urban, and B. Karlan Generating Longitudinal Screening Algorithms Using Novel Biomarkers for Disease Cancer Epidemiol. Biomarkers Prev., February 1, 2002; 11(2): 159 - 166. [Abstract] [Full Text] [PDF]